Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Emphysema

Putting a Novel Emphysema Treatment on the SMAP

“…In this issue of the Journal , Soto and colleagues (pp. 533–544 ) report on the use of two distinct protein phosphatase 2A (PP2A) activators as potential therapeutics for emphysema ( 1 ). PP2A phosphatase activity is decreased with chronic cigarette smoke (CS) exposure and in alpha-1 antitrypsin deficiency (AATD).…”